Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED +0.99%79 PS Ratio is 0.25 as of Jul. 14, 2026, which is 11% below its 10-year median of 0.28. GuruFocus rates XTER:MED with a GF Score™ of 79/100 and a GF Value™ of €3.04 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 658 Healthcare Providers & Services companies, MediClin AG ranks better than 91.79% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MediClin AG's share price is €4.08.
MediClin AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €16.38. Hence, MediClin AG's PS Ratio for today is 0.25.
Warning Sign:
MediClin AG stock PS Ratio (=0.25) is close to 3-year high of 0.26.
The historical rank and industry rank for MediClin AG's PS Ratio or its related term are showing as below:
XTER:MED'
s PS Ratio Range Over the Past 10 Years
Min: 0.15 Med: 0.28 Max: 0.51
Current: 0.25
During the past 13 years, MediClin AG's highest PS Ratio was 0.51. The lowest was 0.15. And the median was 0.28.
XTER:MED's PS Ratio is ranked better than 91.79% of 658
companies
in the Healthcare Providers & Services industry
Industry Median: 1.475
vs XTER:MED: 0.25
MediClin AG has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of MediClin AG was 5.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 3.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.20% per year.
During the past 13 years, MediClin AG's highest 3-Year average Revenue per Share Growth Rate was 5.10% per year. The lowest was -9.60% per year. And the median was 2.90% per year.
Back to Basics: PS Ratio
MediClin AG (XTER:MED) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
MediClin AG PS Ratio Related Terms
MediClin AG PS Ratio Historical Data
* Premium members only.
The historical data trend for MediClin AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, MediClin AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where MediClin AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
MediClin AG's Share Price of today is €4.08. MediClin AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
MediClin AG (XTER:MED) has a PS Ratio of 0.25 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MediClin AG and its competitors. This is 11% below median its historical median of 0.28. Over the past decade, MediClin AG's PS Ratio has ranged from 0.15 to 0.51. According to the industry distribution chart, MediClin AG ranks #54 out of 658 companies in the Healthcare Providers & Services industry, placing it in the top 8.2%.
Is MediClin AG's PS Ratio too high?
MediClin AG's current PS Ratio of 0.25 is 11% below median its 10-year median of 0.28. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.51. The Healthcare Providers & Services industry median PS Ratio is 1.48. MediClin AG's value of 0.25 is 83.1% below this industry median. Based on the distribution chart, MediClin AG ranks #54 out of 658 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, MediClin AG has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's PS Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #54 out of 658 companies for PS Ratio. This places MediClin AG in the top 8% of its industry — outperforming the majority of peers. The industry median PS Ratio is 1.48. MediClin AG's value of 0.25 is 83.1% below this benchmark. Historically, MediClin AG's own PS Ratio has ranged from 0.15 to 0.51 over the past decade. While the company's 10-year median is 0.28 vs. the industry median of 1.48, MediClin AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.48, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediClin AG's current PS Ratio of 0.25 is 83.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current PS Ratio is 0.25, which is 11% below median its own 10-year median of 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.04, compared to a current price of €4.08 — trading 34.2% above its estimated fair value. The current PS Ratio is 0.25, which is 11% below median its 10-year median of 0.28 and 83.1% below the Healthcare Providers & Services industry median of 1.48. MediClin AG's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current PS Ratio is 0.25 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €4.08 is trading 34.2% above its estimated GF Value™ of €3.04.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
PS Ratio: 0.25 (11% below median its 10-year median of 0.28)
GF Value™: €3.04 vs. price of €4.08 (34.2% above fair value)
Industry Position: 83.1% below the Healthcare Providers & Services median (#54 of 658)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
79GF Score
Get the complete analysis for XTER:MED
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
